Search Browse Earnings

Intra-Cellular Therapies, Inc. — SlamSEC

Intra-Cellular Therapies, Inc.

Pharmaceutical Preparations·BEDMINSTER, NJ

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$250.3M

+198.7% YoY

FY 2024

Adj. EBITDA

-$263.0M

-105.1% margin

FY 2024

Net Income

-$256.3M

-102.4% margin

FY 2024

EPS (Diluted)

-$2.72

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$148.6M

FY 2024

Total Debt

—

Net Cash

$148.6M

FY 2024

Enterprise Value

—

Debt / EBITDA

0.6x

FY 2024

EV / EBITDA

—

Employees

—